investor presentation - jefferies · this presentation contains forward-looking statements about...

INVESTOR PRESENTATION

JUNE 2019

2

Forward-looking statements

This presentation contains forward-looking statements about BeyondSpring Inc. (“BeyondSpring” or the “Company”). Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to ourmanagement, including those described in the forward-looking statements and risk factors sections of the Company’s 20-F andother filings with the United States Securities and Exchange Commission (SEC), which are available on BeyondSpring’s InvestorRelations website.

Such statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’sactual results, levels of activity, performance, or achievements to be materially different from those anticipated by suchstatements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,”“expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “intends,” or “continue,” or the negative ofthese terms or other comparable terminology. Forward-looking statements contained in this presentation include, but are notlimited to, (i) statements regarding the timing of anticipated clinical trials for our product candidates and our research anddevelopment programs; (ii) the timing of receipt of clinical data for our product candidates; (iii) our expectations regarding thepotential safety, efficacy, or clinical utility of our product candidates; (iv) the size of patient populations targeted by our productcandidates and market adoption of our product candidates by physicians and patients; and (v) the timing or likelihood ofregulatory filings and approvals.

Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update thereasons why actual results could differ materially from those anticipated in the forward-looking statements, even if newinformation becomes available in the future.

3

Agenda

Plinabulin

NSCLC

CIN: Study 105 (Phase 2) – Intermediate Risk Chemotherapy

Commercial Opportunities

Company Overview

CIN: Study 106 (Phase 2) – High Risk Chemotherapy

4

BeyondSpring is well positioned to capture the significant market potential with severe unmet medical needs

Plinabulin – a First-in-Class asset

Late stage global registrational trials targeting unmet medical needs

Pipeline in a drug Patent protection in major markets

Strong pipeline and platform

Early-stage pipeline for IO combos potentially enhances efficacy and safety profile

Pioneer in ubiquitination pathway platform

Visible near term milestones

NSCLC: China and U.S. NDA submissions expected in 2019 and 2020, respectively

CIN: China and U.S. NDA submissions expected in 2019 and in 2020, respectively

1Differentiated MoA

Unique mechanism leading to both CIN and anti-cancer effect

Differentiated from other T.B. Data presented at major conferences

2

World-class execution

One global multi-center trial to support parallel filings in U.S. and China

CROs & CMOs meeting U.S. GCP/GMP standards

3

Strong validation by KOLs and FDA

Trials led by world renowned KOLs as principal investigators

Potential inclusion in NCCN guideline Record trial initiation speed

4

Superior trial data support

Superiority in efficacy and safety with statistical significance

Consistent trend in multiple trials Comprehensive safety database

56

Visionary senior management

Deep industry knowledge and experience

Together brought 30+ drugs to the global market

8

7

5

Robust drug development pipeline

Note: 1 We own global rights to Plinabulin in all countries except China. In China, we own a 60% interest in our Chinese subsidiary, Wanchun Bulin, which owns a 100% interest in Plinabulin.

Program Indication Trial name Preclinical Phase 1 Phase 2 Phase 3 Commercial rights

China NDA filing

U.S. NDA filing

Late

stag

e

Plinabulin + docetaxel NSCLC

(2nd/3rd line)Study 103 Global1 2019 2020

Plinabulin

CIN

Study 105

Global1 2019 2020

Plinabulin + pegfilgrastim Study 106

Inve

stig

ator

-initi

ated

IO Plinabulin + nivolumabNSCLC

(2nd/3rd line)

Fred Hutch/Univ.

Washington/UCSDGlobal1

Plinabulin + nivolumab + ipilimumab SCLC Rutgers University Global1

Plinabulin + pembrolizumab + chemo

NSCLC (1st line) Johns Hopkins Global1

Oth

er o

ncol

ogy

pipe

line

Ubiquitination platform Target KRAS Univ. Washington /NYU Global

BPI-002 Oral CTLA-4 inhibitor Global

BPI-003 IKK inhibitor Global

BPI-004 Neo-antigen generator Global

Phase 3 first interim data analysis completed

Phase 3 primary end point met at interim analysis

Phase 2 efficacy / safety end points met

6

Visionary management team

Gordon Schooley,Ph.D.

Kenneth Lloyd, Ph.D.

Ramon Mohanlal, M.D., Ph.D.

Lan Huang, Ph.D.

James Tonra, Ph.D.

Co-founder, Chairman & Chief Executive Officer

Co-founded CRO Paramax and sold to RPS, co-founded Wuxi MTLH and sold self-designed peptide drug to Shanghai Pharmaceutical

Board member of Oncology Drug Review Board of China Pharma Assoc

Trained at UC Berkeley and MSKCC

Chief Medical Officer & EVP, Research and Development

More than 20 years experience in strategic drug development, including executive positions at GSK and Vertex

Previously Head of Established Products Oncology for Novartis

Chief Scientific Officer

Greater than 45 years experience in pharmaceutical industry drug discovery and development

Previously held executive and scientific positions at Roche, Synthelabo, Wyeth-Ayerst, SIBIA, and Nereus

Chief Regulatory Officer

Executive for more than 20 years leading clinical and regulatory affairs

Previously held executive and regulatory positions at SkyePharma, Alliance Pharmaceutical and Pacira Pharma

SVP, Preclinical Development

20+ years of experience in biotechnology research

Leading research efforts at Regeneron, Millennium and ImClone

Authored 40+ peer-reviewed publications and led 8 IND filings and clinical strategy development

Edward Liu

Chief Financial Officer

Over a decade of experience in global capital markets, equity financing, M&A, and healthcare investment

Previously senior banker at J.P. Morgan and Jefferies

Former Partner and Executive Director at a cross-border healthcare focused fund

Richard Daly

Chief Operating Officer

25+ years of experience heading BD and commercial operations for leading pharmaceutical companies

Former Executive Vice President at Takeda U.S. and President of AstraZeneca’s U.S. Diabetes subsidiary

10 product launches and 8 strategic alliances

Lihua Du

China General Manager

30 years of experience in drug development, clinical and regulatory affairs in China

Participated in approvals of 12 marketed drugs in China

7

World renowned scientific advisors and principal investigators

Douglas Blayney, M.D.

Jeffrey Crawford, M.D.

Yuankai Shi, M.D.

Yan Sun, M.D. Avram Hershko, M.D.

Principal Investigator, Study 105 & Study 106

Founding member and former Board Member of the NCCN Guidelines for Neutropenia Management in U.S.

Former president of ASCO

Former member of the FDA’s Oncologic Drugs Advisory Committee

Medical Director of Stanford Cancer Institute

DSMB Chairman, Study 105 & Study 106

Chairman of NCCN Guidelines for Neutropenia Management in U.S.

Lead investigator of the U.S. multicenter, randomized trial of Filgrastim (G-CSF, Neupogen), leading to FDA approval

Professor of Medicine at Duke University

Principal Investigator, Study 105 & 106 China

Chairman of the NCCN Guidelines for Neutropenia Management in China

Director of Oncology Department at Cancer Hospital Chinese Academy of Medical Sciences

SAB Member, Study 103

Chairman of NCCN Guideline for NSCLC and Board of Directors of NCCN Guideline

Alex Grass Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University

Principal Investigator, Study 103 China

Chairman of the NCCN Guidelines for NSCLC in China

Co-founder of the Steering Committee of the Chinese Society of Clinical Oncology (CSCO)

Director of GCP Center at Cancer Hospital of Chinese Academy of Medical Sciences

SAB Member, Ubiquitination Platform

Nearly 50 years of research leadership in ubiquitination pathway

2004 Nobel Prize in Chemistry for discovery of ubiquitin-mediated protein degradation

Distinguished Professor at Rappaport Faculty of Medicine at Technion in Haifa

David Ettinger, M.D.

8

Agenda

Plinabulin Overview

NSCLC



Company Overview


9

Plinabulin profile

Small molecule

Inexpensive to manufacture

Given by IV infusion

Used in 500+ cancer patients to-date with good tolerability

Currently in Phase 3 in two indications

Potential for multiple cancer indications

76 patents granted globally, 20 patents issued in U.S. Issued and allowed U.S. patents directed to composition of matter, polymorph

synthesis and use are scheduled to expire between 2021 and 2036 (excluding any potential patent term restoration)

Pending: target, new use

10

Plinabulin: first-in-class agent with GEF-H1 as new target

Note: 1 Chang et al., 2008 Mol Biol Cell; Kashyap et al., 2018 submitted. 2 Zhang et al., 2005 Mol Cell Biol. 3 Keystone Meeting, Mar 2017; Kashyap et al. 2018 submitted. 4 Singh et al., 2011 Blood. 5 Keystone Meeting, Mar 2017; Unpublished findings: University of Basel. 6 Keystone Meeting, Mar 2017. 7 Suwa et al., 2000 Am J Physiol Heart Circ Physiol; Ghosh et al., 2018 ACR Annual Conference; Blayney et al., Society of Leukocyte Biology. 8 Asensi et al., 2004 Infection and Immunity.

Dendritic cell maturation3

GEF-H1 activation1

Rho/ROCK activation1

T cell activation3

Kill cancercells5

Kill cancer cells4

IL-6 activation6

Accelerate neutrophil maturation7

Neutrophil demargination7

JNK activation2

Microtubules

Delay neutrophil apoptosis8

Plinabulin

11

Agenda

Plinabulin Overview

NSCLC



Company Overview


12

NSCLC: potential large market opportunity for Plinabulin

Plinabulin + docetaxel

EGFR wild typemOS = 6-8 months

70% of Asian patients85% of Western patients

2nd / 3rd line NSCLC

PD-1/PD-L120% of patients

EGFR mutant mOS = 18.3 months

30% of Asian patients15% of Western patients

Current approved therapies

Approved therapies do not address the vast majority of NSCLC genotypes; creating a significant opportunity:

Effectiveness only in specific tumor mutations

Limited patient response in many patients

Unique safety risks across therapeutic modalities

Plinabulin targeted patients

Plinabulin being explored in the 2nd line and 3rd line:

EGFR wild type patients account for 70%-85% of patient population

Patients with measurable lung lesions based on RECIST 1.1 criteria, with tumor over 1cm at CT scan (around 70% of NSCLC patients, according to Phase 2 data)

13

Approved therapies fail to address EGFR wild type NSCLC (80-90% of western patients) in 2nd and 3rd lines

Only four treatments are currently approved: docetaxel, pemetrexed, ramucirumab and PD-1

Nivolumab (PD-1) vs.

docetaxel1

Pemetrexedvs.

docetaxel2

Ramucirumab + docetaxel

vs.docetaxel3

Plinabulin +docetaxel

vs.docetaxel

mOS+2.8 months

（12.2 vs. 9.4）+0.4 months（8.3 vs. 7.9）

+1.4 months（10.5 vs. 9.1）

+4.6 months（11.3 vs. 6.7）

ORR 19% vs.12% 9.1% vs. 8.8% 23% vs. 14% 18.4% vs.10.5%

Grade 3/4 neutropenia 0% vs. 27% 5% vs. 40% 49% vs. 39% 7% vs. 26%

DOR 17 vs. 6 months 4.6 vs. 5.3 months 12.7 vs. 1 months

80% patients refractory to PD-1/PD-L1

Approved based on low grade 3/4 neutropenia

Approved based on 1.4 months OS benefit

Study 101: Phase 2 data

Note: 1 NEJM 373: 1627-1639 (2015). 2 JCO 22(9): 1589-1597 (2004). 3 Lancet 384 (9944): 665-673 (2014).

Moving into 1st line 2nd & 3rd lines

14

Study 101 (phase 2): Plinabulin safety summary

As of now, Plinabulin generally well tolerated (> 500 patients); no cardio adverse effects with two-year follow-up

AEs are dose-dependent and manageable

Grade 3/4 Adverse Event (AE) as % in patients

Plinabulin 20mg/m2 (2 doses) + docetaxel 75mg/m2

(n=40)

Plinabulin 30mg/m2 (2 doses) + docetaxel 75mg/m2

(n=50)Docetaxel 75mg/m2

(n=73)

Nausea (N) 0 4 0Vomiting (V) 0 4 1Diarrhea (D) 5 8 6Constipation 0 0 1Anorexia 3 0 0Fatigue 3 4 10Asthenia 13 2 4Arthralgia 0 0 0Myalgia 0 2 0Headache 3 0 0Dizziness 0 0 0Dyspnea 5 4 14Cough 0 0 0Alopecia 0 0 0Hypokalemia 5 0 1Anemia 5 8 2Leukopenia 0 2 9Neutropenia 5 8 26Pyrexia 0 0 2Tachycardia 0 0 0Transient Hypertension (TH) 5 20 0

Increased AE Reduced AE

15

Study 103: phase 3 in NSCLC – first interim data analysis completed; DSMB recommended trial to continue

# of patients & sites Approximately 550 patients in 60 sites in U.S., Australia and China

Patient enrollment Patients with at least 1 measurable lung lesion; 2nd-/3rd-line NSCLC

PD-1/PD-L1 antibody failures (stratified)

EGFR wild type, mutations not eligible; no restriction on histology

One prior platinum-based chemotherapy; no restriction on biological therapy

SAP Plan: KRAS mutant subgroup; PD-L1 expression subgroup; tumor size subgroup; prior treatment include PD-1/PD-L1 or not

Primary objective Overall survival

Secondary objective Grade 4 neutropenia (C1D8), DOR, QoL questionnaires, ORR, PFS

Dosing cohorts Arm 1 – docetaxel (75 mg/m2)

Arm 2 – docetaxel (75 mg/m2) + Plinabulin (30 mg/m2)

Pre-specified interim analysis First look: at 1/3 patients mortality, sample size will re-adjust if hazard ratio (HR) > 0.75 based on mOS

Second look: at 2/3 patients mortality, study will stop if p <= 0.012 for mOS

Status First interim data analysis completed; second interim data readout in 2H 2019

Phase 3 study (randomized single blinded)

16

Agenda

Plinabulin Overview

NSCLC



Company Overview


17

Study 105: phase 2/3 in neutropenia (intermediate risk chemo)Primary objective met at interim analysis

# of patients & sites 55 patients in 43 sites

Patient enrollment Patients with 2nd/3rd line NSCLC

Primary objective To establish the Recommended Phase 3 Dose (RP3D) based on PK/PD analysis

Dosing cohorts Arm 1 – Docetaxel (75 mg/m2) + Neulasta® (pegfilgrastim) (6 mg) (n=14)

Arm 2 – Docetaxel (75 mg/m2) + Plinabulin (5 mg/m2) (n=14)



Status Completed

Phase 2 study (randomized open label)

# of patients & sites Approximately 105 patients in 55 sites

Patient enrollment Patients with 2nd line breast cancer, 1st line prostate cancer or 2nd/3rd line NSCLC

Primary objective DSN in cycle 1, non-inferiority margin of 0.65 days

Secondary objectives Incidence of grade 4 neutropenia, febrile neutropenia, infection, antibiotic use, docetaxel dose change

Incidence and duration of hospitalization due to febrile neutropenia

Incidence and severity of bone pain

Dosing cohorts Arm 1 – Docetaxel (75 mg/m2) + Neulasta® (pegfilgrastim) (6 mg) (n=75)

Arm 2 – Docetaxel (75 mg/m2) + Plinabulin (RP3D) (n=75)

Status Primary objective met at interim analysis

Phase 3 study (randomized double blinded)

One dose Plinabulin per cycle, 30 minutes after chemotherapy on day 1, 30 minutes IV infusion

18

Study 105 (phase 2): Plinabulin 20mg/m2 had similar incidence of neutropenia as Neulasta

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

1 2 3 4

% o

f pat

ient

s

Grade

Neulasta 6mg (n=14) Plinabulin 20mg/m2 (n=14)

Plinabulin 10mg/m2 (n=13) Plinabulin 5mg/m2 (n=14)

% of incidence of neutropenia in cycle 1 after Docetaxel for NSCLC

19

Study 105 (phase 2): Plinabulin 20mg/m2 showed superior safety profile compared to Neulasta

% incidence in thrombocytopenia in cycle 1

0%5%

10%15%20%25%30%

Grade 1 Grade 2 Grade 3 Grade 4Neulasta 6mg (n=14) Plinabulin 20mg/m2 (n=14)

0%

5%

10%

15%

20%

25%

30%

35%

40%

1 2 3 4 5 6 7 8 9

% o

f pat

ient

s

Day

Neulasta 6mg (n=14)Plinabulin 20mg/m2 (n=14)

% of bone pain in cycle 1 after Docetaxel for NSCLCNeutrophil to lymphocyte ratio (NLR) in cycle 1

NLR>5 -> immune suppressive

20

Study 105 (phase 2): Plinabulin demonstrated a clear superiority profile against Neulasta, standard of care

Neulasta Plinabulin 20mg/m2

DSN (grade 4) 0.5 day 0.5 day

% neutropenia (grade 4) 14% 14%

% bone pain Yes No from day 3

Thrombocytopenia Yes No

Immune suppression Yes No

Anti-cancer No Yes

Plinabulin demonstrates a clear superiority profile in cycle 1 after Docetaxel for NSCLC

21

Agenda

Plinabulin Overview

NSCLC



Company Overview


22

Severe unmet medical needs – vast majority of patients in high risk chemo “escape” standard of care today

Note: 1 Masuda N et al., Support Care Cancer 23: 2891-2898 (2015). 2 Lee J et al., Annals of Surgical Treatment and Research 94(5): 223-238 (2018). 3 Kirshner et al., Comm Onc 4:455-459 (2007). 4 Xu et al., Support Care Cancer 24:723-730 (2016). 5 Lalami et al., Critical Reviews in Oncology / Hematology 120 163-179 (2017). 6 O’Regan et al., Clinical Breast Cancer 6(2): 163-168 (2005). 7 Vasey et al., British J Cancer 87: 1072-78 (2002). 8 Alba et al. JCO 22(13): 2587-93 (2002). 9 Moore et al, Annals of Pharmacotherapy 51(9): 797-803 (2017).

Efficacy Neulasta 6.0 mg1

n=29Neulasta 6.0 mg2

n=61

Neutropenia (grade 3/4) 96.6% 100%

DSN 1.4 ± 0.7 1.8 ± 1.2

Mean ANC nadir (109/L) 0.255 ± 0.287 0.266

Neulasta after TAC for breast cancer

Limited choices to manage bone pain: NSAIDs (causing blood clots), antihistamine (mixed results), opioids (not allowed), Neulasta dose reduction (higher risk of FN)9

Safety Neulasta 6.0 mg3

n=100Neulasta 6.0 mg4

Bone pain (score of 1-10) 59% 71%

Severe bone pain (score of 6-10) 24% 27%

Neulasta after chemotherapy

Guidelines for grade 3/4 neutropenia is to reduce or delay chemotherapy dosing by 5-7 days5

In cancer patients with <85% relative dose intensity (RDI), patient survival is 50% of those with >=85% RDI5

TAC is a very effective chemo treatment with ORR at 84%6, but because of its high severe neutropenia rate, TAC needs to be changed to less effective TC (with ORR at 42%)7 and TA (with ORR at 51%)8

23

Study 106: phase 2/3 in neutropenia (high risk chemo)Efficacy and safety objections met at top line analysis


Patient enrollment Patients with 1st line breast cancer

Primary objective To establish the Recommended Phase 3 Dose (RP3D) based on PK/PD analysis

Dosing cohorts Arm 1 – TAC + Neulasta® (pegfilgrastim) (6 mg)

Arm 2 – TAC + Plinabulin (10 mg/m2)



Arm 5 – TAC + Plinabulin (20 mg/m2) + Neulasta® (pegfilgrastim) (1.5 mg)

Arm 6 – TAC + Plinabulin (20 mg/m2) + Neulasta® (pegfilgrastim) (3 mg)

Arm 7 – TAC + Plinabulin (20 mg/m2) + Neulasta® (pegfilgrastim) (6 mg) (the “Plinabulin / Neulasta Combo”)

Status Efficacy and safety objectives met at top line analysis

Phase 2 study (randomized open label)


Patient enrollment Patients with 1st line breast cancer

Primary objective Non-inferiority first; if met, superiority in cycle 1 DSN

Dosing cohorts Arm 1 – TAC + Neulasta® (pegfilgrastim) (6 mg)

Arm 2 – TAC + Plinabulin/Neulasta® RP3D

Status To be initiated, final data readout in 2H 2019

Phase 3 study (randomized double blinded)

One dose Plinabulin per cycle, 30 minutes after chemotherapy on day 1, 30 minutes IV infusion

24

Study 106 (phase 2): Plinabulin and Neulasta has complimentary absolute neutrophil count (ANC) profile

Median ANC in cycle 1 after TAC for breast cancer

0.0

1.0

2.0

3.0

4.0

5.0

6.0

7.0

6 7 8 9 10

Med

ian

ANC

(109

cells

/L)

Day in cycle 1

Neulasta 6mg (n=21) Plinabulin 30mg/m2 (n=12)

Plinabulin 20mg/m2 (n=15) Plinabulin 10mg/m2 (n=15)

Grade 3 Neutropenia (> 0.5 & < 1.0)

Grade 4 Neutropenia (< 0.5)

25

Study 106 (phase 2): Plinabulin / Neulasta Combo enhanced absolute neutrophil count (ANC) profile

Median ANC in cycle 1 after TAC for breast cancer

0.0

1.0

2.0

3.0

4.0

5.0

6.0

7.0

6 7 8 9 10

Med

ian

ANC

(109

cells

/L)

Day in cycle 1

Neulasta 6mg (n=21) Plinabulin 20mg/m2 + Neulasta 6mg (n=16)

Plinabulin 20mg/m2 + Neulasta 3mg (n=21) Plinabulin 20mg/m2 + Neulasta 1.5mg (n=14)

Grade 3 Neutropenia (> 0.5 & < 1.0)

Grade 4 Neutropenia (< 0.5)

26

Study 106 (phase 2): Plinabulin / Neulasta Combo demonstrated positive efficacy data in prevention of CIN

81%

50%

Neulasta6mg

(n=21)

Plinabulin 20mg/m2 +Neulasta 6mg

(n=16)

% incidence of grade 3/4 neutropenia in cycle 1 after TAC for breast cancer

p = 0.0456

Duration of grade 3/4 neutropenia in cycle 1 after TAC for breast cancer (days)

1.38

0.94

Neulasta6mg

(n=21)

Plinabulin 20mg/m2 +Neulasta 6mg

(n=16)

Reduction of 36%

27

Study 106 (phase 2): Plinabulin / Neulasta Combo demonstrated positive safety data in prevention of CIN

At lease X days of bone pain in cycle 1 after TAC for breast cancer

95%

38%

6%0%

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

1 2 3 4 5 6 7 8

% o

f pat

ient

s

At least X days of bone pain

Neulasta 6mg (n=21) Plinabulin 20mg/m2 + Neulasta 6mg (n=16)

p < 0.0001

p = 0.0056

28

Study 106 (phase 2): Plinabulin / Neulasta Combo demonstrates a clear superiority profile against Neulasta, standard of care

Neulasta Plinabulin / Neulasta Combo

DSN (grade 3/4) Over 1 day Less than 1 day

% neutropenia (grade 3/4) High (> 80%) Low (50%)

Median ANC nadir (109 cells/L) 0.47 (> 50% with grade 4 neutropenia)1.00 (> 50% avoid grade 3/4

neutropenia)

% bone pain Almost all Limited

Immune suppression Yes Limited

Anti-cancer No Yes

Plinabulin / Neulasta Combo demonstrates a clear superiority profile after TAC for breast cancer

29

Agenda

Plinabulin Overview

NSCLC



Company Overview


30

Rising global incidence of non-small cell lung cancer

2015 NSCLC market size by region1, 3

55.9%

22.0%

23.6%

U.S. Europe Japan + China

Global NSCLC market size and growth ($ billion)2

$0$5

$10$15$20$25$30$35$40

17 18 19 20 21 22 23 24 25 26US Japan France Germany Italy Spain UK

~1.8 million lung cancer diagnoses globally, 87% NSCLC

Sales of key NSCLC drugs across the U.S., Japan, and five major EU markets totaled $11.5bn in 2017 and expected to increase to $33.9bn by 2026

Increasing incidence of NSCLC and use of premium-priced checkpoint inhibitor therapies, particularly in the 1st line setting, are the major drivers of growth

Nearly 1/3 of global patients are in China: $445mm sales in 2015; projected to be $4.3bn in 20253

Source: GlobalData; 2DatamonitorNote: 1 Market share by regions broken out into the 8 major markets for NSCLC: France, Germany, Italy, Japan, Spain, UK and U.S. 3 China NSCLC market forecast.

31

Global neutropenia market

CIN market = $7 billion in 2017 (mainly used with high risk chemo)

China and the U.S. represent 2/3 of all G-CSF global therapy

Plinabulin positioning: Plinabulin as mono or combo therapy improves on the standard of care in the treatment of Chemotherapy Induced Neutropenia; potential for improved chemotherapy outcome

Addressable market

Combination with G-CSF to

Improved neutropenia

Reduced bone pain

Improve compliance & persistency with chemo

Global

G-CSF cycles/year = 4.3 million1

G-CSF market value = $7 billion

Plinabulin + G-CSF: reduced neutropenia and improved bone pain; potential for improved compliance and persistency with chemo

Plinabulin: reduced bone pain; improved thrombocytopenia and immune function

Canada$140M/yr G-CSF market

80K G-CSF cycles/yr

EU 5$870M/yr G-CSF market

850K G-CSF cycles/yr

South Korea$46M/yr G-CSF market

18% peg growth YoY78K G-CSF cycles/yr

United States$5+B/yr G-CSF market1.3M G-CSF cycles/yr

China$350M/yr G-CSF market

20% cycle growth YoY33% $ G-CSF growth YoY

1.6M G-CSF cycles/yr

Australia$40M/yr G-CSF market

53K G-CSF cycles/yr

Japan$240M/yr G-CSF market

7% peg growth YoY330K G-CSF cycles/yr

Note: 1 https://onlinelibrary.wiley.com/doi/full/10.3322/caac.21338. G-CSF market growth based on IQVIA data and DDM MD data Q3 ‘16 to Q2 ’18. Standardized G-CSF units

32

THANK YOU

investor presentation - jefferies · this presentation contains forward-looking statements about...

Documents